Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Imagine yourself as a passive income investor looking for a medical stock with significant share growth potential. Wall ...

Keros Therapeutics' stock has plummeted over 70% due to safety issues in its phase 2 PAH study, halting all trial arms. Learn more about KROS stock here.

Notably, Merck's Winrevair pulmonary arterial hypertension (PAH) medication is on track to be the company's next blockbuster drug, already delivering $419 million in sales in just the first two ...

I also want to point out the excellent news related to Winrevair (sotatercept), which is, in turn, the flagship of Merck's cardiovascular franchise. On January 30 of this year, it announced that ...

We recently compiled a list of the 12 Undervalued Wide Moat Stocks to Buy According to Analysts. In this article, we are ...

Medicare Part D redesign is expected to hurt sales by approximately $400 million, primarily affecting Winrevair and oncology products, including Welireg, Lynparza and Lenvima. Merck expects top ...

Merck & Co., Inc. (NYSE ... Its Keytruda drug for cancer treatment is performing well, and the launch of Winrevair, a drug that treats pulmonary arterial hypertension (PAH), is also boosting ...

Merck is one of the world's leading pharmaceutical ... primed and ready to bring new medications to market. One example is Winrevair, which is designed to fight adult pulmonary-arterial hypertension.